Skip to main content
Cellectis logo

Cellectis — Investor Relations & Filings

Ticker · ALCLS ISIN · FR0010425595 LEI · 5493000KKX5VQ37Q2W83 PA Manufacturing
Open in API
Filings indexed 1,324 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country FR France
Listing PA ALCLS

About Cellectis

https://cellectis.com/en

Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.

Recent filings

Filing Released Lang Actions
Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire
Regulatory Filings Classification · 55% confidence The document is a corporate press release announcing that Cellectis received FDA RMAT designation for its therapy candidate. It does not include financial results, regulatory filings like a 10-K or interim report, nor does it announce board changes, dividends, share issues, etc. It is not a publication announcement of a formal report, nor a management discussion. It is a general regulatory news-style announcement about FDA status. It therefore best fits the fallback category for miscellaneous regulatory announcements (RNS).
2026-06-09 French
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the FDA’s RMAT designation for a therapy candidate. It contains no financial statements, no shareholder vote or management changes, no earnings data, and no detailed report attached. It is an event-driven regulatory announcement. It does not qualify as an Annual or Interim Report, Earnings Release, Proxy or Dividend Notice, or any M&A or financing update. As such, it falls under the fallback category for general regulatory announcements (RNS).
2026-06-09 English
FORM 6-K
Regulatory Filings Classification · 87% confidence The document is a U.S. SEC Form 6-K submitted by a foreign private issuer, providing a press release as Exhibit 99.1. It does not itself include substantive financial data or fit a more specific category. Under the taxonomy, Form 6-K filings and miscellaneous regulatory disclosures fall into Regulatory Filings (RNS).
2026-06-09 English
Monthly information on share capital and company voting rights
Regulatory Filings Classification · 90% confidence The document is a short regulatory announcement under Article 223-16 of the French AMF, providing the monthly update of total shares and voting rights. It is not a full report or a shareholder vote result, nor a new share issuance notice; rather it is a compliance/regular regulatory filing. Therefore it falls under Regulatory Filings (RNS).
2026-06-03 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Regulatory Filings Classification · 90% confidence The document is a monthly regulatory update under Article 223-16 of the AMF, listing the total number of shares and voting rights. It is not announcing a share issuance, voting results, or any meeting materials, but rather a routine compliance disclosure. This fits the catch-all category for general regulatory announcements.
2026-06-03 French
L’Assemblée Générale Mixte de Cellectis se tiendra le le 25 juin 2026
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a press release announcing the date and venue of Cellectis’s Mixed General Meeting (Assemblée Générale Mixte) on June 25, 2026. It is not the meeting materials themselves, nor the results, but a notice sent to shareholders providing information about the meeting and to solicit attendance/votes. This fits the definition of a Proxy Solicitation & Information Statement (PSI) rather than an AGM presentation, voting result declaration, or regulatory fallback.
2026-05-20 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.